This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
THCV
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict WATCH-LIST LOW
Interesting "anti-munchies" CB1 antagonist with metabolic benefits in Phase 2 obesity + T2D trials. Now widely available in vape + edible products from cannabis dispensaries; concentration in commercial product varies enormously. For Dylan with no metabolic indication, no current case. Worth knowing because: (a) the appetite-suppressant cannabinoid niche could become a real product class, (b) novel CB1-antagonist mechanism distinct from rimonabant (which was withdrawn for depression/suicide signal) since THCV partial agonism may avoid that.
▸ Verdict change log
- 2026-06-05 — Initial verdict WATCH-LIST. (stub)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.